



**The Centre for Eye and Vision Research and SCOPE Health Inc  
Sign a MoU to Develop and Commercialize Novel Product Technologies  
for the Treatment of Dry Eye and Ocular Surface Conditions**

**HONG KONG and NEW YORK, December 9, 2024**—The [Centre for Eye and Vision Research \(CEVR\)](#) and [SCOPE Health Inc.](#) have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions. By leveraging SCOPE's knowledge and expertise in eye drop product formulation science, together with CEVR's extensive experience in ocular drug discovery and delivery translational research, the pair are committed to developing innovative product approaches for doctor and patient unmet ocular surface disease needs.

Professor Ben Thompson, CEO and scientific director of CEVR, remarked, “We are thrilled to collaborate with SCOPE Health Inc., a leading innovator in management solutions for ocular surface diseases. Through this collaboration and SCOPE's ardent support, engagement in areas such as dry eye management at the practice level and global outreach will increase substantially to deliver tangible change. The research results will advance CEVR's mission to develop technologies that preserve and enhance vision worldwide. This partnership merges cutting-edge science with formulation and commercialization expertise, paving the way for a transformative solution to support developing technologies that preserve and enhance healthy vision worldwide.”

Tom Freyne, CEO of SCOPE Health Inc., said, “Disrupting the status quo and establishing a new standard of care for ocular surface diseases requires collective efforts. Under the leadership of CEVR's Principal Investigators, Prof. Lyndon Jones, and Dr. Chau-Minh Phan, along with Dr. Howard Ketelson, head of Ideation & Discovery at SCOPE, this collaboration collectively harnesses our expertise's to develop and commercialize differentiated and clinically valued eyecare products.”

**About the Centre for Eye and Vision Research**

[Centre for Eye and Vision Research \(CEVR\)](#) is a research collaboration between The Hong Kong Polytechnic University and the University of Waterloo in Canada under the InnoHK initiative of the HKSAR Government. It is located at the Hong Kong Science Park, Shatin, Hong Kong. It is the first global hub performing ground-breaking research in five key areas: myopia and eye growth, ocular drug discovery and delivery, vision enhancement, tear film and ocular surface, and advanced

optometric technology. The mission of CEVR is to generate technologies to prevent vision loss in the aging population and preserve healthy vision. Learn more at [www.cevr.hk](http://www.cevr.hk).

### **About Scope Eyecare**

[SCOPE Health Inc.](http://www.scopehealth.com) is an international healthcare company founded in Ireland in 2009. It offers innovative products for the management of ocular surface disease (e.g., dry eye/blepharitis/MGD) and age-related macular degeneration. [SCOPE](http://www.scopehealth.com) maintains a reputation for providing premium products and innovation to enhance the lives of patients. With a focus on fostering long-term relationships with health care professionals to advance eye health and drive successful results. Learn more at [www.optase.com](http://www.optase.com).

### **Press Contact**

Ms. Sabrin Tsui

Marketing Manager, CEVR

+852 5208 6310

[amm@cevr.hk](mailto:amm@cevr.hk)



## **CEVR and SCOPE Health Inc Sign a MoU**

to Develop and Commercialize Novel Product Technologies  
for the Treatment of Dry Eye and Ocular Surface Conditions

